WO2020036229A1 - 乳酸菌、血中鉄増加剤、及び貧血改善剤 - Google Patents
乳酸菌、血中鉄増加剤、及び貧血改善剤 Download PDFInfo
- Publication number
- WO2020036229A1 WO2020036229A1 PCT/JP2019/032181 JP2019032181W WO2020036229A1 WO 2020036229 A1 WO2020036229 A1 WO 2020036229A1 JP 2019032181 W JP2019032181 W JP 2019032181W WO 2020036229 A1 WO2020036229 A1 WO 2020036229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- iron
- acid bacterium
- present
- anemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Definitions
- the present invention relates to a lactic acid bacterium, a blood iron increasing agent, and an anemia improving agent. More specifically, the present invention relates to a lactic acid bacterium, a blood iron increasing agent, and an anemia ameliorating agent which have high food suitability, are easy to produce, can increase the iron concentration in blood, and can improve anemia.
- the stored iron mainly serum ferritin
- hemoglobin and serum iron leading to iron deficiency anemia.
- a state of low stored iron is said to be a latent iron deficiency that does not cause anemia symptoms (so-called “hidden iron deficiency”), and it is not a disease, but “somehow tired”, “inefficient work”, In some cases, this may cause physical inconsistency (unfixed complaint) such as "not motivated”.
- hidden iron deficiency a latent iron deficiency that does not cause anemia symptoms
- this may cause physical inconsistency (unfixed complaint) such as "not motivated”.
- reduced iron stores are also associated with insomnia and depression. Such “lack of hidden iron” has become a very serious problem in the modern age of women's advancement in society.
- iron deficiency Known causes of iron deficiency include dietary imbalance. In order to eliminate the iron deficiency, it is important to improve eating habits and to lead a correct eating habit. To improve dietary habits, aggressive consumption of animal foods such as meat and fish meat rich in iron (heme iron) with a good absorption rate, vegetables, beans, It is important that seaweed and the like be taken together with vegetables that contain a lot of vitamins that enhance absorption.
- iron preparations are effective.
- taking iron preparations may cause gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea, and constipation as side effects. Therefore, iron preparations may not be easily taken.
- vitamin C may be used in combination to enhance the absorption effect of iron.
- vitamin C is decomposed by stomach acid, so it is expected that the effect is not taken in large quantities such as 1000 mg / time. There is a problem that can not be.
- the causes of sports anemia are as follows: (1) Athletes need more iron because they have a lot of activity, but iron loss due to sweat during exercise (iron deficiency anemia), (2) blood Red blood cells are physically destroyed, resulting in anemia (motile hemolytic anemia). It is known that this motor hemolytic anemia tends to occur particularly in sports in which the soles of the feet are strongly impacted (marathon, long-distance sports such as athletics, volleyball, soccer, basketball, karate, kendo, etc.).
- hemoglobin most of iron in the body is present in red blood cells as hemoglobin, and serves to transport oxygen to the whole body.
- blood iron increasing agent refers to a substance having an effect of increasing the iron content in blood (including heme iron represented by hemoglobin, stored iron such as filitin and hemosiderin, and serum iron). Means that.
- a lactic acid bacterium as a component of a blood iron-increasing agent and an anemia ameliorating agent without side effects, for example, iron deficiency including fermented milk obtained using a lactic acid bacterium belonging to Lactobacillus acidophilus.
- a composition for treating anemia has been reported (for example, see Patent Document 1). Since this lactic acid bacterium has been conventionally ingested through foods, it has the advantages of high safety for the human body and low concern about side effects.
- lactic acid bacteria have been used for a long time to produce fermented foods and are ingested through the fermented foods. Lactic acid bacteria are known to have a variety of effects, and specifically report on intestinal action / improvement of intestinal microflora, cholesterol reduction, anti-obesity effect, cognitive function improvement effect, beauty effect, etc. Have been. It is also known that lactic acid bacteria have an effect of improving immunity (allergy improvement, cancer prevention, infection protection).
- the composition for treating iron deficiency anemia described in Patent Literature 1 requires a step of preparing fermented milk using the lactic acid bacterium at the time of production thereof, and thus requires equipment and time for fermentation. is there. Furthermore, the lactic acid bacterium itself used for producing the composition for treating iron deficiency anemia described in Patent Literature 1 also needs to have a sufficiently prepared environment or a strict treatment of a culture solution during its growth. There is a problem that it takes time and effort to manufacture.
- the present invention provides a lactic acid bacterium capable of increasing blood iron concentration and improving anemia, a blood iron increasing agent containing the lactic acid bacterium, and an anemia improving agent containing the lactic acid bacterium.
- lactic acid bacteria an agent for increasing blood iron, and an anemia improving agent.
- a blood iron-increasing agent containing the lactic acid bacterium according to any one of [1] to [5].
- the lactic acid bacteria of the present invention have high food suitability (ie, high safety) and are easy to produce because they are easily cultured. Furthermore, the lactic acid bacterium of the present invention can increase iron concentration in blood and can improve anemia.
- the blood iron-increasing agent of the present invention contains the lactic acid bacterium of the present invention, it has high food suitability (that is, high safety) and is easy to produce, and can further increase blood iron concentration, It can improve anemia.
- the anemia ameliorating agent of the present invention contains the lactic acid bacterium of the present invention, it has high food suitability (that is, high safety) and is easy to produce, and can further increase the iron concentration in blood and reduce anemia. It can be improved.
- Lactic acid bacteria The lactic acid bacterium of the present invention is a salt-tolerant lactic acid bacterium that increases the iron concentration in blood. This lactic acid bacterium has high food suitability (that is, high safety) and is easy to produce because it is easily cultured. Furthermore, the lactic acid bacterium of the present invention can increase iron concentration in blood and can improve anemia. In addition, the lactic acid bacterium in the present invention may be Tetragenococcus halophilus. "Blood iron concentration” means the concentration of serum iron, the concentration of stored iron (filitin, hemosiderin, etc.), and the concentration of heme iron represented by hemoglobin.
- the composition for treating iron deficiency anemia described in Patent Document 1 contains fermented milk, and a predetermined lactic acid bacterium is used when producing the fermented milk. Therefore, it is not disclosed that the lactic acid bacterium itself participates in iron absorption. On the other hand, the present invention is such that a predetermined lactic acid bacterium exhibits the above-mentioned effect.
- the lactic acid bacterium of the present invention has salt tolerance, so that it can be cultured in an environment having a high salt concentration, which is an environment in which contaminating bacteria are unlikely to grow, and in a state where the growth of contaminating bacteria is suppressed. Easy to culture.
- “increases blood iron concentration” means that continuous intake of lactic acid bacteria orally increases blood iron concentration before and after ingestion.
- increase the blood iron concentration specifically, it is preferable that the blood iron concentration is significantly increased, and more specifically, the test was performed by a Wilcoxon signed rank test. However, it is preferable to say that it has the ability to increase the iron concentration in blood so that there is a significant difference at a risk rate (significance level) of 5% or less.
- “having salt tolerance” means having a property that allows culturing in a medium having a high salt concentration (specifically, a salt concentration of 11 w / v% or more). Regarding the degree of salt tolerance, it is preferable that the growth rate when cultured in a medium having a salt concentration of 12 w / v% is 30 times or more.
- the lactic acid bacteria of the present invention can be, for example, those isolated in the brewing process of miso (especially rice miso).
- Specific examples of the salt-tolerant lactic acid bacteria isolated in the brewing process of rice miso include “Kurahana Lactic Acid Bacteria LTK-1” (trade name, manufactured by Ichibiki Co., Ltd.).
- Lactic acid bacteria "isolated in the miso brewing process” refer to lactic acid bacteria having salt tolerance that are established in the "kura,” “muro,” “tub,” etc. in the miso brewing process. Furthermore, it refers to a bacterium that can grow in the ripening step from the preparation of miso.
- the “lactic acid bacteria isolated in the brewing process of miso” can also be referred to as salt-tolerant lactic acid bacteria contained in miso (ie, miso lactic acid bacteria).
- salt-tolerant lactic acid bacteria derived from miso ie, miso-derived lactic acid bacteria
- Salt-tolerant lactic acid bacteria Salt-tolerant lactic acid bacteria).
- the lactic acid bacteria "isolated in the brewing process of miso" are not limited to those isolated in the brewing process of miso, but are isolated in the brewing process of miso and then cultured (subculture). Including those that have been done.
- the lactic acid bacterium of the present invention is not particularly limited as long as it is a lactic acid bacterium that increases the iron concentration in blood and has salt tolerance.
- the lactic acid bacterium of accession number NITE @ BP-02318 and the accession number NITE @ BP-03010 are not limited. Lactic acid bacteria (ICK-3 strain), ICK-4 strain, ICK-5 strain, No. 185 strains, No. 259 strains, no.
- Specific examples of such a salt-tolerant lactic acid bacterium include Tetragenococcus halophilus.
- the lactic acid bacterium having the accession number NITE @ BP-02318 was deposited on August 3, 2016 (domestic date of deposit) with the Patented Microorganisms Depositary Center (NPMD) of the National Institute of Technology and Evaluation, September 6, 2017. As of today, it has been transferred to an international deposit under the Budapest Treaty.
- the lactic acid bacterium having the accession number NITE @ BP-03010 has been internationally deposited on August 5, 2019 with the Patent Microorganisms Depositary Center (NPMD) of the National Institute of Technology and Evaluation.
- the lactic acid bacteria of the present invention may be dead cells or live cells.
- the culture conditions for the lactic acid bacterium of the present invention are not particularly limited.
- the lactic acid bacterium can be cultured in a medium having a salt concentration of 11 to 18 w / v%, preferably at a salt concentration of 11 to 16 w / v%, and preferably 12 to 14 w / V% is particularly preferred.
- w / v% means (mass (g) / volume (100 mL))%.
- lactic acid bacteria of the present invention When cultured under such conditions, other bacteria (contaminating bacteria such as various bacteria) are unlikely to proliferate, while the lactic acid bacteria of the present invention can be cultured, so that the lactic acid bacteria of the present invention can be cultured simply and favorably mainly. it can. Furthermore, culturing at a salt concentration within the above range prevents enrichment of contaminating bacteria that do not have salt tolerance, while bacteria having salt tolerance such as salt-tolerant Staphylococcus bacteria (salt-tolerant bacteria). (Contaminating bacteria). That is, even in the case of a salt-tolerant contaminant, the culture can be terminated and recovered before the contaminant multiplies.
- contaminating bacteria When cultured in a medium having a salt concentration of less than 11 w / v%, contaminating bacteria tend to grow easily, and it tends to be difficult to secure a sufficient yield. In addition, when cultured in a medium having a salt concentration of more than 18 w / v%, contaminating bacteria are more difficult to proliferate. Also.
- lactic acid bacteria of the present invention can be cultured efficiently and in large quantities.
- the culturing temperature is preferably 20 to 40 ° C, more preferably 28 to 37 ° C.
- the culturing time is about 24 to 120 hours, and stirring may be performed during the culturing.
- the pH of the medium is preferably 5 to 9, and more preferably 6 to 7.
- a medium containing a nitrogen source and a carbon source can be used.
- the nitrogen source is not particularly limited, and examples thereof include soy sauce, miso, meat extract, peptone, gluten, casein, yeast extract, amino acids, and the like.
- the carbon source is not particularly limited, and includes, for example, glucose, koji digestion solution, saccharified solution of rice, sucrose, starch, starch syrup, glycerin and the like.
- the inorganic material may contain, for example, an inorganic salt such as sodium acetate, magnesium, manganese, iron, or the like, or may contain vitamins.
- the lactic acid bacteria of the present invention can be prepared by performing a treatment such as sterilization after culturing. Specifically, after completion of the cultivation, the medium components containing the salt are removed by means such as centrifugation, and the cells are washed and purified. Then, heat sterilization is performed, and thereafter, drying and concentration are performed by means such as freeze drying, reduced pressure drying, and hot air drying. Thus, the lactic acid bacteria of the present invention can be prepared.
- the heat sterilization is not particularly limited, but specifically, autoclave sterilization (121 ° C., 20 minutes) or similar sterilization is preferable.
- Lactic acid bacteria intake period The lactic acid bacterium of the present invention is preferably taken for 2 weeks or more, more preferably for 4 weeks or more.
- the blood iron-increasing agent of the present invention contains the lactic acid bacterium of the present invention, and can increase blood iron concentration by ingesting it for a certain period of time. And since the said lactic acid bacteria are easy to culture because of their salt tolerance, the production of the blood iron enhancer of the present invention using the lactic acid bacteria is facilitated. And the blood iron-increasing agent of the present invention, by containing the lactic acid bacterium of the present invention, can increase the iron concentration in blood, and as a result, also exerts the effect of improving anemia. .
- Lactic acid bacteria The blood iron-increasing agent of the present invention contains the lactic acid bacterium of the present invention described above as an active ingredient. By employing this lactic acid bacterium, the iron concentration in blood can be increased, and as a result, anemia can be improved. Furthermore, by adopting this lactic acid bacterium, safety is high and production becomes easy. In addition, a lactic acid bacterium may contain one kind of strain, or may contain two or more kinds of strains.
- the content of the blood iron-increasing agent of the present invention is not particularly limited as long as it contains the lactic acid bacterium of the present invention as an active ingredient, and can be determined as appropriate.
- the lactic acid bacterium of the present invention can be contained so that about 10 billion (equivalent to about 2.5 mg) to about 5 trillion (equivalent to about 1.25 g) of bacteria can be taken at one time.
- the blood iron increasing agent may be taken orally before or after a meal as a medicine or supplement.
- the blood iron-increasing agent of the present invention may contain a culture, a cell or a cell component obtained by the method for culturing lactic acid bacteria of the present invention.
- the blood iron-increasing agent of the present invention may be composed solely of the lactic acid bacterium of the present invention (or containing a culture or the like), or may contain other components in addition to the lactic acid bacterium of the present invention.
- components that are appropriately blended according to uses such as pharmaceuticals, quasi-drugs, and foods and beverages can be employed.
- other components include, for example, excipients, coating agents, binders, extenders, disintegrants, surfactants, lubricants, diluents, dispersants, buffers, Osmotic pressure adjusters, pH adjusters, emulsifiers, preservatives, stabilizers, antioxidants, colorants, ultraviolet absorbers, humectants, thickeners, activity enhancers, anti-inflammatory agents, bactericides, flavoring agents, odor correction Agents and the like.
- the combined use with an iron salt is effective.
- the iron salt may be any of an inorganic iron salt and an organic iron salt.
- an active ingredient or a pharmacological component other than the lactic acid bacterium of the present invention may be contained.
- other components include, for example, sweeteners, acidulants, carbon dioxide, inorganic salts, flavors, fruit juices, vitamins, antioxidants, esters, pigments, emulsifiers, preservatives, seasonings, and vegetable extracts. , Nectar extract, quality stabilizer, bitterness inhibitor and the like.
- the active ingredient and pharmacological component other than the lactic acid bacteria of the present invention may be contained as long as the object of the present invention is not impaired.
- the blood iron-increasing agent of the present invention can be taken in any form (oral or parenteral).
- solid forms such as tablets, coated tablets, granules, powders and capsules, and liquid forms such as elixirs and syrups may be mentioned.
- the blood iron-increasing agent of the present invention can be produced, for example, by a method including a lactic acid bacteria preparation step and a raw material preparation step.
- a blood iron increasing agent can be easily produced.
- This method does not require a step of obtaining fermented milk using lactic acid bacteria, as compared with the method for producing a composition for treating iron deficiency anemia described in Patent Document 1, and eliminates time and equipment for fermentation. It can be said to be a simple method.
- lactic acid bacteria themselves have the advantage of being easy to culture because they have salt tolerance.
- the lactic acid bacteria preparing step is a step of preparing the lactic acid bacteria of the present invention described above.
- the lactic acid bacterium may be prepared by obtaining a seed bacterium and culturing the seed bacterium by the method described above, or purchasing a commercially available lactic acid bacterium (for example, trade name “Kurahana lactic acid bacterium LTK-1” (manufactured by Ichibiki)). You may prepare by doing the same.
- the raw material preparation step is a step of mixing the lactic acid bacterium of the present invention prepared in the lactic acid bacterium preparation step and other components as necessary to prepare a raw material for a blood iron increasing agent.
- this step is unnecessary when the blood iron-increasing agent of the present invention is composed of only the lactic acid bacteria of the present invention (or those containing a culture or the like).
- the method for producing the composition for treating iron deficiency anemia described in Patent Document 1 it is necessary to prepare a raw material by mixing fermented milk and an iron salt.
- this step is not required, and the production is also easy in this respect.
- a step (state forming step) for forming a solid form may be adopted after the raw material preparation step.
- the blood iron-increasing agent of the present invention is preferably taken for 2 weeks or more, more preferably for 4 weeks or more.
- Anemia improving agent contains the lactic acid bacterium of the present invention, and when taken for a certain period of time, increases the iron concentration in the blood, thereby improving anemia (particularly, iron deficiency anemia). What you get. And since the said lactic acid bacteria are easy to culture because of their salt tolerance, the production of the anemia ameliorating agent of the present invention using the lactic acid bacteria is facilitated. And the anemia ameliorating agent of the present invention can increase the iron concentration in blood by containing the lactic acid bacterium of the present invention, and as a result, exerts the effect of improving anemia.
- the anemia improving agent of the present invention contains the lactic acid bacterium of the present invention, but may also contain the blood iron increasing agent of the present invention.
- the lactic acid bacterium of the present invention can be contained so that about 10 billion (equivalent to about 2.5 mg) to about 5 trillion (equivalent to about 1.25 g) of bacteria can be taken at one time.
- the anemia improving agent may be taken orally before or after a meal as a pharmaceutical or supplement.
- the anemia improving agent of the present invention contains the above-mentioned lactic acid bacterium of the present invention as an active ingredient.
- the iron concentration in blood can be increased, and as a result, anemia can be improved.
- the use of the lactic acid bacterium of the present invention makes the anemia improving agent highly safe and easy to produce.
- a lactic acid bacterium may contain one kind of strain, or may contain two or more kinds of strains.
- the content of the anemia ameliorating agent of the present invention is not particularly limited as long as it contains the lactic acid bacterium of the present invention as an active ingredient, and can be appropriately determined.
- the anemia improving agent of the present invention may contain a culture, a cell or a cell component obtained by the method for culturing lactic acid bacteria of the present invention.
- the anemia ameliorating agent of the present invention may be composed solely of the lactic acid bacterium of the present invention (or containing a culture or the like), or may contain other components in addition to the lactic acid bacterium of the present invention.
- components that are appropriately blended according to uses such as pharmaceuticals, quasi-drugs, and foods and beverages can be employed.
- other components include, for example, excipients, coating agents, binders, extenders, disintegrants, surfactants, lubricants, diluents, dispersants, buffers, Osmotic pressure adjusters, pH adjusters, emulsifiers, preservatives, stabilizers, antioxidants, colorants, ultraviolet absorbers, humectants, thickeners, activity enhancers, anti-inflammatory agents, bactericides, flavoring agents, odor correction Agents and the like.
- the combined use with an iron salt is effective.
- the iron salt may be any of an inorganic iron salt and an organic iron salt.
- an active ingredient or a pharmacological component other than the lactic acid bacterium of the present invention may be contained.
- other components include, for example, sweeteners, acidulants, carbon dioxide, inorganic salts, flavors, fruit juices, vitamins, antioxidants, esters, pigments, emulsifiers, preservatives, seasonings, and vegetable extracts. , Nectar extract, quality stabilizer, bitterness inhibitor and the like.
- the active ingredient and pharmacological component other than the lactic acid bacteria of the present invention may be contained as long as the object of the present invention is not impaired.
- the anemia improving agent of the present invention can be taken in any form (oral or parenteral).
- oral or parenteral solid forms such as tablets, coated tablets, granules, powders and capsules, and liquid forms such as elixirs and syrups may be mentioned.
- the anemia improving agent of the present invention may be prepared by mixing the above-mentioned blood iron increasing agent of the present invention with the other components, or the blood iron increasing agent of the present invention may be used as it is. (That is, it may be composed only of the blood iron increasing agent of the present invention).
- the anemia ameliorating agent of the present invention can be produced by the same method as the method for producing a blood iron-increasing agent of the present invention.For example, it can be produced by a method comprising a lactic acid bacteria preparation step and a raw material preparation step. it can. By such a production method, an anemia improving agent can be easily produced.
- This method does not require a step of obtaining fermented milk using lactic acid bacteria, as compared with the method for producing a composition for treating iron deficiency anemia described in Patent Document 1, and eliminates time and equipment for fermentation. It can be said to be a simple method.
- lactic acid bacteria themselves have the advantage of being easy to culture because they have salt tolerance.
- the lactic acid bacteria preparing step is a step of preparing the lactic acid bacteria of the present invention described above.
- the lactic acid bacterium may be prepared by obtaining a seed bacterium and culturing the seed bacterium by the method described above, or purchasing a commercially available lactic acid bacterium (for example, trade name “Kurahana lactic acid bacterium LTK-1” (manufactured by Ichibiki)). You may prepare by doing the same.
- the raw material preparation step is a step of mixing the lactic acid bacterium of the present invention prepared in the lactic acid bacterium preparation step and other components as necessary to prepare a raw material for an anemia ameliorating agent.
- this step is unnecessary when the anemia ameliorating agent of the present invention is composed of only the lactic acid bacterium of the present invention (or one containing a culture or the like).
- the method for producing the composition for treating iron deficiency anemia described in Patent Document 1 it is necessary to prepare a raw material by mixing fermented milk and an iron salt.
- this step is not required, and the production is also easy in this respect.
- a step (state forming step) for forming a solid form may be adopted after the raw material preparation step.
- the anemia improving agent of the present invention is preferably taken for 2 weeks or more, more preferably for 4 weeks or more.
- Serum iron concentration serum iron concentration before and after ingestion of lactic acid bacteria (day 14 and day 28) was measured for 20 healthy Japanese people aged 20 to 45 years old. The serum iron concentration was measured using a colorimetric method.
- the method of ingestion is as follows: tablets containing the lactic acid bacteria of the present invention (specifically, the lactic acid bacteria of accession number NITE @ BP-02318) under the trade name "Kurahana lactic acid bacteria LTK-1" (manufactured by Ichibiki Co., Ltd.) ) Was orally taken together with 10 tablets (containing 1250 mg of "Kurahua lactic acid bacteria LTK-1") per day. The intake period was 28 days. Table 1 shows the results.
- the components of the tablet taken orally are as follows. 41.7% by mass of trade name “Kuraka lactic acid bacterium LTK-1”, 39.0% by mass of dextrin, 15.0% by mass of powdered cellulose, 2.0% by mass of sucrose fatty acid ester, 2% of fine silicon dioxide 0.0% by mass and 0.3% by mass of shellac.
- the lactic acid bacteria-containing tablet of the present invention (blood iron increasing agent, anemia ameliorating agent) after ingestion (on the 14th and 28th days from the start of ingestion) was compared with before the ingestion. It can be seen that the serum iron concentration is significantly increased.
- those containing the lactic acid bacteria of the present invention can favorably increase serum iron concentration. Therefore, it can be seen that it is effective in improving anemia (particularly, iron deficiency anemia) (it can be used as an anemia improving agent).
- lactic acid bacteria having trade name “Kurahana lactic acid bacterium LTK-1” and accession number NITE BP-03010 (hereinafter referred to as “ICK-3 strain” or “ICK-3”)
- ICK-3 strain or “ICK-3”
- ICK-4 strain sometimes referred to as "ICK-4"
- ICK-5 strain sometimes referred to as "ICK-5"
- Soy sauce (trade name “Ikubiki Shoyu” manufactured by Ichibiki) is used as a nitrogen source and trace minerals, and glucose (manufactured by Kanto Kagaku) is used as a carbon source. ) And water. In this way, a medium consisting only of food ingredients was prepared.
- the above-mentioned medium is prepared by mixing the soy sauce, glucose, and salt with water so that the soy sauce is 20 v / v%, the glucose is 1.7 w / v%, and the salt concentration is 12 w / v%. After mixing, the mixture was adjusted to have a pH of 7.0 with a food additive sodium hydroxide (manufactured by Kanto Chemical Co., Ltd.).
- 10SG10N plate medium is soy sauce (trade name “Koikuchi Shoyu” manufactured by Ichibiki Co., Ltd.) 10 v / v%, glucose 1.0 w / v%, yeast extract 1.0 w / v%, polypeptone 0.5 w / v% , Sodium acetate trihydrate 0.2 w / v%, sodium chloride 10 w / v%, "Tween 80" 0.0025 w / v%, magnesium sulfate heptahydrate 0.02 w / v%, manganese sulfate tetrahydrate
- the pH was 6.8 and the content of agar was 2 w / v%, containing 0.001 w / v% and 0.001 w / v% iron sulfate heptahydrate.
- Example 2 Nine healthy long-distance athletes aged 22 to 27 years before (2 months, 4 months, 6 months) and after (2 months, 4 months) intake of lactic acid bacteria A blood test was performed. This blood test was performed once every two months as described above.
- Tables 3 to 6 show the results of hemoglobin, serum iron, and ferritin before and after ingestion of lactic acid bacteria among the blood test items.
- the “mean value before ingestion” is the average of the blood tests performed three times before ingestion of lactic acid bacteria (performed two months, four months, and six months before ingestion). Indicates that the average is the average.
- the “average value after ingestion start” is an average of the average values of the blood test performed twice after ingestion of lactic acid bacteria (performed at the second and fourth months from the start of ingestion of lactic acid bacteria). Indicates that
- the “mean value before the start of ingestion” is the average of the blood tests (performed two months before, four months, and six months before the start of ingestion) performed three times before the ingestion of lactic acid bacteria (A -I) are shown below.
- two months after the start of ingestion indicates the results of each of the blood tests (A to I) performed on the second month from the start of ingestion of the lactic acid bacteria.
- “4 months after the start of ingestion” indicates the results of blood tests performed by each of the individuals (A to I) four months after the start of ingestion of lactic acid bacteria.
- the method of ingesting lactic acid bacteria is as follows: tablets containing the product name “Kurahana lactic acid bacteria LTK-1” (manufactured by Ichibiki Co., Ltd.), which is the lactic acid bacterium of the present invention (specifically, the lactic acid bacterium of accession number NITE @ BP-02318), Two tablets per day (containing 250 mg of "Kurahua lactic acid bacterium LTK-1") were orally ingested together with water as an iron-increasing agent and an anemia improving agent. The ingestion period is 4 months as described above. In addition, the meal during the test consumed a normal meal which is not different from usual.
- the components of the tablet taken orally are as follows. 41.7% by mass of trade name “Kuraka lactic acid bacterium LTK-1”, 39.0% by mass of dextrin, 15.0% by mass of powdered cellulose, 2.0% by mass of sucrose fatty acid ester, 2% of fine silicon dioxide 0.0% by mass and 0.3% by mass of shellac.
- Tables 3 to 6 show the results of the blood test.
- Table 3 shows the change in serum iron concentration.
- Table 4 shows the change in ferritin concentration.
- Tables 5 and 6 show changes in hemoglobin concentration.
- Sperum iron concentration is a value measured by a colorimetric method.
- Feritin concentration is a value measured by CLIA (chemiluminescence immunoassay).
- Hemoglobin concentration is a value measured by the SLS-hemoglobin method.
- the concentration of serum iron after ingesting the lactic acid bacteria of the present invention is higher than before taking the tablets containing the lactic acid bacteria of the present invention (blood iron increasing agent, anemia improving agent). It turns out that there is a tendency.
- the ferritin concentration after ingesting the lactic acid bacteria of the present invention is significantly increased as compared with before taking the tablets containing the lactic acid bacteria of the present invention (blood iron increasing agent, anemia improving agent).
- the concentration of hemoglobin after ingesting the lactic acid bacteria of the present invention tends to increase as compared with before taking the tablets containing the lactic acid bacteria of the present invention (blood iron increasing agent, anemia improving agent). It turns out that there is.
- Table 6 shows the results of the blood test for each of the subjects A to I. According to the blood test performed four months after the start of lactic acid bacteria ingestion, hemoglobin was found in eight out of nine subjects. It can be seen that the concentration tends to increase. In particular, it is considered that the tendency is apparent in the subjects B, G, and I.
- Example 3 The test in this example was a double-blind parallel group comparison test. Among the Japanese women aged 20 years and over and 59 years and under, 14 subjects (test subjects) who were judged to be "mild anemia" having a hemoglobin value of less than 12 g / dL and a serum ferritin of less than 12 ng / mL And These 14 persons were divided into two groups (Group A and Group B).
- test subjects in group A were asked to take the tablet test food (containing the lactic acid bacterium of the present invention) orally twice daily with water every day
- group B control The test subjects in the food intake group
- the ingestion period was 8 weeks.
- the component ratio of the orally ingested tablets is as follows.
- Test food The test food was 41.7% by mass of the trade name “Kuraka lactic acid bacteria LTK-1” (manufactured by Ichibiki Co., Ltd.), 39.0% by mass of dextrin, 15.0% by mass of powdered cellulose, and 2.50% of sucrose fatty acid ester. 0% by mass, 2.0% by mass of fine silicon dioxide, and 0.3% by mass of shellac.
- the control food was 79.7% by mass of dextrin, 15.0% by mass of powdered cellulose, 2.0% by mass of sucrose fatty acid ester, 2.0% by mass of fine silicon dioxide, and 1.0% by mass of caramel pigment. And shellac was 0.3% by mass.
- hemoglobin the values of hemoglobin, serum iron, reticulocyte count, total iron binding capacity (total iron binding capacity (TIBC)), and serum ferritin before and eight weeks after the start of ingestion were measured.
- Hemoglobin was measured by the SLS-hemoglobin method, reticulocyte count was measured by flow cytometry, serum iron was measured by colorimetry, and TIBC was measured by colorimetry.
- the serum ferritin was measured using CLIA (chemiluminescence immunoassay). Table 7 shows the results.
- Example 4 A three-week-old female mouse (C57BL / 6JJcl) was divided into eight groups, each containing five mice. All mice in all groups were fed with a low-iron diet (powder) for three weeks, and an anemia model mouse in an anemia state was obtained. Produced. For the next two weeks, the animals were bred with the following feeds. Tables 9 to 12 show the combination of low iron feed (powder) and normal diet. Table 9 shows the composition of the feed (low iron feed (powder), normal diet), Table 10 shows the composition of the mineral Mix of the low iron feed (powder) and the normal diet, and Table 11 shows The content of the vitamin Mix in the feed is shown. Table 12 shows the iron content in the feed (low iron feed (powder), normal diet).
- a group fed a low iron feed containing 0.2% by mass of a lactic acid bacterium (trade name “Kurahana lactic acid bacterium LTK-1” (trade name, manufactured by Ichibiki Co., Ltd.)) under the accession number NITE @ BP-02318 was referred to as “LTK-1 diet group”
- the group fed a low iron feed containing 0.2% by mass of the lactic acid bacterium "ICK-3” was referred to as an "ICK-3 diet group”
- a low iron feed containing 0.2% by mass of the salt-tolerant lactic acid bacterium "ICK-4" was used.
- the group given the “ICK-4 diet group”, and the group fed the low iron feed containing 0.2% by mass of the salt-tolerant lactic acid bacterium “ICK-5” was the “ICK-5 diet group”. Furthermore, three strains (No. 185 strain (sometimes described as “No. 185”), No. 259 strain (sometimes described as “No. 259”), and No. 448 strain (“No. 448”) ) was also evaluated.
- the group fed the low iron feed containing 0.2% by mass of the salt-tolerant lactic acid bacterium “No. 185” was referred to as “No. 185 meal group”, and the group containing 0.2% by mass of the salt-tolerant lactic acid bacterium “No.
- the group to which the iron feed was given was designated as "No.
- the lactic acid bacteria used in this example all belong to Tetragenococcus halophilus.
- a group to which a normal diet (“Basal feed CE-2” manufactured by Nippon Clea Co., Ltd.) was taken was defined as a “normal diet group”.
- This normal diet group is mice that have not been fed an low-iron diet (powder) and are not in anemia.
- the breeding environment of the mice in each group was the same, specifically, as follows.
- the temperature was set at 20 to 26 ° C.
- the humidity was set at 45 to 70% (except for short-term changes such as during disinfection), and the ventilation rate was set at 10 to 15 times / hour.
- the illumination time was set to 7:00 to 19:00 in a bright time zone and from 9:00 to 7:00 in a dark time zone.
- the microbiological grade is Specific pathogen free animals (SPF) (experimental animals are aseptically bred), the breeding rack uses a vinyl isolator (Max 8 gauge), and the breeding gauge is mouse PC (182 ⁇ 260). ⁇ 128 mm).
- Drinking water was supplied after filling a water supply bottle (250 cc), sterilizing by high pressure steam (121 ° C., 30 minutes). The timing of water supply was one line / two times / week.
- the feeder used a cage-dedicated lid, the floor bedding used a planar chip (one that had been sterilized by high-pressure steam at 121 ° C. for 30 minutes), and the cage was replaced once a week.
- Blood is collected three weeks after the start of breeding (ie, when the feed is switched) and five weeks (ie, two weeks after the feed is switched), and a blood cell counter for animals (a fully automatic blood cell counter) "Celltac @ ⁇ @ MEK" is used. -6458 (manufactured by Nihon Kohden Co., Ltd.), and the hemoglobin concentration in blood was measured. Table 8 shows the results.
- the blood hemoglobin concentration was increased in all the groups ingesting the lactic acid bacteria having salt tolerance as compared with the low iron diet group.
- the blood hemoglobin concentration was significantly increased in the LTK-1 diet group, the ICK-3 diet group, the ICK-4 diet group, and the ICK-5 diet group as compared with the low iron diet group. From these results, it was found that LTK-1, ICK-3, ICK-4, ICK-5, No. 185, no. 259, no. It was confirmed that ingestion of a feed containing a lactic acid bacterium having a salt tolerance such as 448 exhibited an anemia improving effect. In particular, it is considered that the lactic acid bacteria LTK-1, ICK-3, ICK-4, and ICK-5 have a high effect of improving anemia.
- the lactic acid bacteria of the present invention (blood iron increasing agent of the present invention) have an effect of increasing the amount of iron in human serum when taken orally for a predetermined period. Furthermore, the results shown in Table 1 indicate that the lactic acid bacteria of the present invention (the blood iron-increasing agent of the present invention) can be used to improve anemia (particularly, iron deficiency anemia).
- those containing the lactic acid bacteria of the present invention can satisfactorily increase serum iron concentration, ferritin concentration, and hemoglobin concentration. I understand. From this, it can be seen that it is effective in improving anemia (particularly, iron deficiency anemia) (it can be used as an anemia improving agent).
- those containing the lactic acid bacterium of the present invention can improve the sports anemia of athletes and those who are engaged in sports for health by increasing the iron content in the blood. It is effective (can be used as an anemia improving agent).
- the endurance athlete who is an athlete such as a long-distance run, aims to efficiently transport oxygen in the body and enhance aerobic exercise, thereby improving the performance of the athlete.
- An effect for example, an effect of improving physical abilities such as endurance
- Example 7 From the results of Example 3 (Table 7), it was found that ingestion of the lactic acid bacteria of the present invention increased serum iron and serum ferritin. From this, according to the lactic acid bacterium of the present invention, improvement of indefinite complaints due to hidden anemia (lack of hidden iron) caused by a decrease in serum ferritin can be expected.
- Example 4 in addition to the lactic acid bacteria with accession number NITE @ BP-02318, the lactic acid bacteria with accession number NITE @ BP-03010 (ICK-3 strain), ICK-4 strain, ICK-5 strain, No. . No. 185 strains, no. 259 strains, no. It can be seen that the 448 strains also have an effect of increasing the amount of iron in serum when taken orally for a predetermined period.
- Example 4 is a test using a mouse, it can be inferred that a similar effect is exhibited in humans.
- the lactic acid bacteria of the present invention can be used as an active ingredient of a blood iron increasing agent and an anemia ameliorating agent.
- the blood iron-increasing agent of the present invention can be used as an agent for increasing the amount of iron in blood.
- the anemia improving agent of the present invention can be used for improving anemia (particularly, iron deficiency anemia).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明の乳酸菌は、血中の鉄濃度を増加させる、耐塩性を有する乳酸菌である。この乳酸菌は、食品適性が高く(即ち、安全性が高く)、培養が簡単であるため製造し易い。更に、本発明の乳酸菌は、血中の鉄濃度を増加させることができ、貧血を改善し得るものである。なお、本発明における乳酸菌は、テトラジェノコッカス・ハロフィラスとすることができる。「血中の鉄濃度」は、血清鉄の濃度、貯蔵鉄(フィリチン、ヘモジデリンなど)、ヘモグロビンに代表されるヘム鉄の濃度を意味する。
本発明の乳酸菌の培養条件は、特に制限はないが、例えば塩分濃度11~18w/v%の培地で培養することができ、塩分濃度11~16w/v%とすることが好ましく、12~14w/v%とすることが特に好ましい。なお、「w/v%」は、(質量(g)/体積(100mL))%を意味する。
本発明の乳酸菌は、培養後、殺菌などの処理を行って調製することができる。具体的には、培養終了後、遠心分離などの手段により食塩を含む培地成分を取り除き、洗浄・精製する。そして、加熱殺菌を行い、その後、凍結乾燥・減圧乾燥・熱風乾燥などの手段により乾燥・濃縮する。このようにして、本発明の乳酸菌を調製することができる。
本発明の乳酸菌は、2週間以上の摂取を続けることが好ましく、4週間以上の摂取を続けることが更に好ましい。
本発明の血中鉄増加剤は、本発明の乳酸菌を含有するものであり、一定期間摂取することで、血中の鉄濃度を増加させることができるものである。そして、上記乳酸菌は、耐塩性であるために培養し易いので、当該乳酸菌を使用する本発明の血中鉄増加剤は、その製造が容易になる。そして、本発明の血中鉄増加剤は、本発明の乳酸菌を含有することによって、血中の鉄濃度を増加させることができ、その結果として貧血を改善し得るという効果も発揮するものである。
本発明の血中鉄増加剤は、上述した本発明の乳酸菌を有効成分として含有するものである。この乳酸菌を採用することによって、血中の鉄濃度を増加させることができ、その結果として貧血を改善し得ることになる。更には、この乳酸菌を採用することによって、安全性が高く、製造が容易になる。なお、乳酸菌としては、一種の菌株を含有してもよいし、二種以上の菌株を含有してもよい。
本発明の血中鉄増加剤は、本発明の乳酸菌(または、培養物等を含むもの)のみから構成されていてもよいし、本発明の乳酸菌以外にその他の成分を含有してもよい。
本発明の血中鉄増加剤は、例えば、乳酸菌準備工程と、原料調製工程と、を備える方法により製造することができる。このような製法により、簡便に血中鉄増加剤を製造することができる。この方法は、特許文献1に記載の鉄欠乏性貧血治療用組成物の製造方法と比べて、乳酸菌を利用して発酵乳を得る工程が不要であり、発酵のための時間や設備などを省略することができるので、簡便な方法ということができる。また、乳酸菌自体についても、耐塩性を有するものであるため、培養が容易であるという利点がある。
本発明の血中鉄増加剤は、2週間以上の摂取を続けることが好ましく、4週間以上の摂取を続けることが更に好ましい。
本発明の貧血改善剤は、本発明の乳酸菌を含有するものであり、一定期間摂取することで、血中の鉄濃度を増加させ、その結果、貧血(特に、鉄欠乏性貧血)を改善し得るものである。そして、上記乳酸菌は、耐塩性であるために培養し易いので、当該乳酸菌を使用する本発明の貧血改善剤は、その製造が容易になる。そして、本発明の貧血改善剤は、本発明の乳酸菌を含有することによって、血中の鉄濃度を増加させることができ、その結果として貧血を改善し得るという効果も発揮するものである。
本発明の貧血改善剤は、上述した本発明の乳酸菌を有効成分として含有するものである。この乳酸菌を採用することによって、血中の鉄濃度を増加させることができ、その結果として貧血を改善し得ることになる。更には、本発明の貧血改善剤は、上記乳酸菌を採用することによって、安全性が高く、製造が容易になる。なお、乳酸菌としては、一種の菌株を含有してもよいし、二種以上の菌株を含有してもよい。
本発明の貧血改善剤は、本発明の乳酸菌(または、培養物等を含むもの)のみから構成されていてもよいし、本発明の乳酸菌以外にその他の成分を含有してもよい。
本発明の貧血改善剤は、本発明の血中鉄増加剤の製造方法と同様の方法によって製造することができ、例えば、乳酸菌準備工程と、原料調製工程と、を備える方法により製造することができる。このような製法により、簡便に貧血改善剤を製造することができる。この方法は、特許文献1に記載の鉄欠乏性貧血治療用組成物の製造方法と比べて、乳酸菌を利用して発酵乳を得る工程が不要であり、発酵のための時間や設備などを省略することができるので、簡便な方法ということができる。また、乳酸菌自体についても、耐塩性を有するものであるため、培養が容易であるという利点がある。
本発明の貧血改善剤は、2週間以上の摂取を続けることが好ましく、4週間以上の摂取を続けることが更に好ましい。
20歳以上で45歳以下の健常な日本人20名を対象に、乳酸菌の摂取前、摂取後(14日目、28日目)における血清中の鉄濃度(血清鉄濃度)を測定した。なお、血清鉄濃度は、比色法を用いて測定した。
培地の塩分濃度を12w/v%とした場合において、商品名「蔵華乳酸菌LTK-1」、受託番号NITE BP-03010の乳酸菌(以下、「ICK-3株」または「ICK-3」と記す場合がある)、「ICK-4株」(「ICK-4」と記す場合がある)、及び、「ICK-5株」(「ICK-5」と記す場合がある)を対象として、増殖倍率の試験を行った。以下に具体的に説明する。
窒素源及び微量ミネラル分として、醤油(イチビキ社製の商品名「こいくちしょうゆ」)、炭素源として、ぶどう糖(関東化学社製)を使用し、その他の原料としては、食塩(関東化学社製)と水を使用した。このようにして食品原料のみからなる培地を作成した。
継代培養を想定して、上記培地で前培養しておいた乳酸菌を1v/v%添加した。このとき初発菌数は1.0×107cfu/mLであった。これを30℃の恒温器の中で20時間静置培養した。
静置培養後、生菌数の測定を行った。生菌数の測定は、「10SG10N平板培地」に希釈菌液を塗布した後、培養(30℃で4日間、嫌気培養)し、その後にコロニー数を計測することで行った。
22~27歳の健康な実業団の長距離競技者9名を対象に、乳酸菌の摂取前(2ヶ月前、4ヶ月前、6ヵ月前)、摂取後(2ヶ月後、4ヶ月後)における血液検査を行った。この血液検査は、上記のように2ヶ月に1回実施した。
本実施例における試験は、二重盲検並行群間比較試験で行った。20歳以上で59歳以下の日本人女性のうち、ヘモグロビン値12g/dL未満であり且つ血清フェリチン12ng/mL未満である「軽度の貧血」と判断された14名を対象者(試験対象者)とした。これら14名を、2群(A群、B群)に振り分けた。その後、A群(被験食品摂取群)の試験対象者には、錠剤の被験食品(本発明の乳酸菌を含むもの)を1日2錠、毎日、水とともに経口摂取してもらい、B群(対照食品摂取群)の試験対象者には、錠剤の対照食品(本発明の乳酸菌を含まないもの)を1日2錠、毎日、水とともに経口摂取してもらった。なお、摂取期間は、8週間とした。
(被験食品)
被験食品は、商品名「蔵華乳酸菌LTK-1」(イチビキ社製)が41.7質量%、デキストリンが39.0質量%、粉末セルロースが15.0質量%、ショ糖脂肪酸エステルが2.0質量%、微粒二酸化ケイ素が2.0質量%、セラックが0.3質量%であった。
(対照食品)
対照食品は、デキストリンが79.7質量%、粉末セルロースが15.0質量%、ショ糖脂肪酸エステルが2.0質量%、微粒二酸化ケイ素が2.0質量%、カラメル色素が1.0質量%、セラックが0.3質量%であった。
3週令の雌マウス(C57BL/6JJcl)を5匹入れた8つの群に分け、全ての群の全てのマウスについて低鉄飼料(粉末)を3週間摂取させ、貧血状態とした貧血モデルマウスを作製した。その後の2週間、以下の各飼料を与えて飼育を行った。なお、表9~表12には、低鉄飼料(粉末)と通常食の配合処方を示す。表9は、飼料(低鉄飼料(粉末)、通常食)の配合内容を示し、表10は、低鉄飼料(粉末)と通常食のそれぞれのミネラルMixの配合内容を示し、表11は、飼料中のビタミンMixの配合内容を示している。また、表12は、飼料(低鉄飼料(粉末)、通常食)中の鉄の含有量を示している。
表1に示すように、本発明の乳酸菌(本発明の血中鉄増加剤)は、所定期間経口摂取することでヒトの血清中の鉄量を増加させる効果があることが分かる。更に、表1に示す結果からすると、本発明の乳酸菌(本発明の血中鉄増加剤)は、貧血(特に、鉄欠乏性貧血)を改善し得るものとして利用できることが分かる。
特許微生物寄託センター
寄託機関のあて名 日本国 〒292-0818
千葉県木更津市かずさ鎌足2-5-8 122号室
寄託日 2017年9月6日
受託番号 NITE BP-02318
(2)寄託機関の名称 独立行政法人製品評価技術基盤機構
特許微生物寄託センター
寄託機関のあて名 日本国 〒292-0818
千葉県木更津市かずさ鎌足2-5-8 122号室
寄託日 2019年8月5日
受託番号 NITE BP-03010。
Claims (7)
- 血中の鉄濃度を増加させる、耐塩性を有する乳酸菌。
- 味噌の醸造工程で単離される請求項1に記載の乳酸菌。
- 塩分濃度12w/v%である培地で培養したときの増殖倍率が30倍以上となる請求項1または2に記載の乳酸菌。
- テトラジェノコッカス・ハロフィラスである、請求項1~3のいずれか一項に記載の乳酸菌。
- 受託番号NITE BP-02318の乳酸菌、または受託番号NITE BP-03010の乳酸菌である請求項1~4のいずれか一項に記載の乳酸菌。
- 請求項1~5のいずれか一項に記載の乳酸菌を含有する血中鉄増加剤。
- 請求項1~5のいずれか一項に記載の乳酸菌を含有する貧血改善剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19849264.7A EP3839042A4 (en) | 2018-08-17 | 2019-08-16 | LACTIC ACID BACTERIA, AGENT TO INCREASE BLOOD IRON LEVELS AND AGENT TO IMPROVE ANEMIA |
KR1020217005716A KR102656118B1 (ko) | 2018-08-17 | 2019-08-16 | 유산균, 혈중 철 증가제, 및 빈혈 개선제 |
US17/267,050 US20210228651A1 (en) | 2018-08-17 | 2019-08-16 | Lactic acid bacterium, blood iron increasing agent, and anemia improving agent |
CN201980053992.5A CN112840017B (zh) | 2018-08-17 | 2019-08-16 | 乳酸菌、血中铁增加剂和贫血改善剂 |
JP2019559123A JP6675521B1 (ja) | 2018-08-17 | 2019-08-16 | 乳酸菌、血中鉄増加剤、及び貧血改善剤 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018153344 | 2018-08-17 | ||
JP2018-153344 | 2018-08-17 | ||
JP2019007716 | 2019-01-21 | ||
JP2019-007716 | 2019-01-21 | ||
JP2019-072472 | 2019-04-05 | ||
JP2019072472 | 2019-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020036229A1 true WO2020036229A1 (ja) | 2020-02-20 |
Family
ID=69524774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/032181 WO2020036229A1 (ja) | 2018-08-17 | 2019-08-16 | 乳酸菌、血中鉄増加剤、及び貧血改善剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210228651A1 (ja) |
EP (1) | EP3839042A4 (ja) |
JP (1) | JP6675521B1 (ja) |
KR (1) | KR102656118B1 (ja) |
CN (1) | CN112840017B (ja) |
WO (1) | WO2020036229A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0525051A (ja) * | 1991-07-19 | 1993-02-02 | Meiji Seika Kaisha Ltd | 貧血予防・治療剤 |
JPH0753391A (ja) | 1993-08-10 | 1995-02-28 | Snow Brand Milk Prod Co Ltd | 鉄欠乏性貧血治療用組成物 |
WO2006080522A1 (ja) * | 2005-01-31 | 2006-08-03 | Kirin Yakult Nextstage Company, Limited | ミネラル含有乳酸菌を含んでなる食品または医薬品 |
JP2008544753A (ja) * | 2005-07-05 | 2008-12-11 | プロビ エービー | Fe、Zn、Caから選択される金属およびこれらのイオンの吸収を増大させるための乳酸桿菌の使用 |
WO2010038714A1 (ja) * | 2008-09-30 | 2010-04-08 | 明治乳業株式会社 | 高いシュウ酸分解能を有する乳酸菌 |
WO2011114916A1 (ja) * | 2010-03-18 | 2011-09-22 | 森永乳業株式会社 | 貧血の予防又は治療用組成物 |
JP2013208071A (ja) * | 2012-03-30 | 2013-10-10 | Ishikawa Prefectural Public Univ Corp | 魚醤から分離した乳酸菌、その培養物及びその利用 |
CN105969687A (zh) * | 2016-05-20 | 2016-09-28 | 西北农林科技大学 | 一种富铁乳酸菌制剂及其生产方法 |
WO2018003899A1 (ja) * | 2016-06-30 | 2018-01-04 | アサヒグループホールディングス株式会社 | 腎性貧血改善用組成物 |
WO2019009328A1 (ja) * | 2017-07-04 | 2019-01-10 | 学校法人順天堂 | 鉄栄養状態改善剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4966679B2 (ja) * | 2007-02-05 | 2012-07-04 | 長野県味噌工業協同組合連合会 | 乳酸菌およびこれを用いる製麹方法 |
WO2016125861A1 (ja) * | 2015-02-06 | 2016-08-11 | 株式会社ゲノム創薬研究所 | 乳酸菌、該乳酸菌由来の自然免疫活性化剤、感染症予防治療剤及び飲食品 |
KR102698401B1 (ko) * | 2016-09-12 | 2024-08-26 | 이치비키 가부시키가이샤 | 내염성 유산균, 내염성 유산균의 배양 방법, 및 면역 부활제 |
JP2018042507A (ja) * | 2016-09-15 | 2018-03-22 | イチビキ株式会社 | 植物性原料に生育しやすいエンテロコッカス属乳酸菌及びその増殖方法、ならびに、それを使用した豆味噌の製造方法および豆味噌 |
GB201616058D0 (en) * | 2016-09-21 | 2016-11-02 | Chain Biotechnology Ltd | Probiotic composition |
JP6846694B2 (ja) * | 2016-09-21 | 2021-03-24 | アダプトゲン製薬株式会社 | 体重又は内臓脂肪増加抑制剤若しくは体重又は内臓脂肪増加抑制用食品組成物若しくは体重又は内臓脂肪増加抑制用飼料組成物 |
-
2019
- 2019-08-16 CN CN201980053992.5A patent/CN112840017B/zh active Active
- 2019-08-16 US US17/267,050 patent/US20210228651A1/en active Pending
- 2019-08-16 JP JP2019559123A patent/JP6675521B1/ja active Active
- 2019-08-16 EP EP19849264.7A patent/EP3839042A4/en active Pending
- 2019-08-16 WO PCT/JP2019/032181 patent/WO2020036229A1/ja unknown
- 2019-08-16 KR KR1020217005716A patent/KR102656118B1/ko active IP Right Grant
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0525051A (ja) * | 1991-07-19 | 1993-02-02 | Meiji Seika Kaisha Ltd | 貧血予防・治療剤 |
JPH0753391A (ja) | 1993-08-10 | 1995-02-28 | Snow Brand Milk Prod Co Ltd | 鉄欠乏性貧血治療用組成物 |
WO2006080522A1 (ja) * | 2005-01-31 | 2006-08-03 | Kirin Yakult Nextstage Company, Limited | ミネラル含有乳酸菌を含んでなる食品または医薬品 |
JP2008544753A (ja) * | 2005-07-05 | 2008-12-11 | プロビ エービー | Fe、Zn、Caから選択される金属およびこれらのイオンの吸収を増大させるための乳酸桿菌の使用 |
WO2010038714A1 (ja) * | 2008-09-30 | 2010-04-08 | 明治乳業株式会社 | 高いシュウ酸分解能を有する乳酸菌 |
WO2011114916A1 (ja) * | 2010-03-18 | 2011-09-22 | 森永乳業株式会社 | 貧血の予防又は治療用組成物 |
JP2013208071A (ja) * | 2012-03-30 | 2013-10-10 | Ishikawa Prefectural Public Univ Corp | 魚醤から分離した乳酸菌、その培養物及びその利用 |
CN105969687A (zh) * | 2016-05-20 | 2016-09-28 | 西北农林科技大学 | 一种富铁乳酸菌制剂及其生产方法 |
WO2018003899A1 (ja) * | 2016-06-30 | 2018-01-04 | アサヒグループホールディングス株式会社 | 腎性貧血改善用組成物 |
WO2019009328A1 (ja) * | 2017-07-04 | 2019-01-10 | 学校法人順天堂 | 鉄栄養状態改善剤 |
Non-Patent Citations (2)
Title |
---|
OKADA SADAMU: "Treatment of Iron Deficiency Anemia", THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNATIONAL MEDICINE, vol. 99, 2010, pages 1220 - 1225 |
See also references of EP3839042A4 |
Also Published As
Publication number | Publication date |
---|---|
EP3839042A4 (en) | 2022-06-01 |
CN112840017A (zh) | 2021-05-25 |
JPWO2020036229A1 (ja) | 2020-08-20 |
KR20210038631A (ko) | 2021-04-07 |
JP6675521B1 (ja) | 2020-04-01 |
EP3839042A1 (en) | 2021-06-23 |
US20210228651A1 (en) | 2021-07-29 |
KR102656118B1 (ko) | 2024-04-11 |
CN112840017B (zh) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111542593B (zh) | 新型双歧杆菌属细菌和包含该细菌的组合物 | |
RU2543815C2 (ru) | Питательные композиции, содержащие лактоферрин и пробиотики, и наборы из их частей | |
CN104758318B (zh) | 一种降低断奶仔猪腹泻率的复合制剂及其制备方法 | |
CN109329419A (zh) | 一种能够维持肠道健康和提高免疫力的功能性益生菌固体饮料及其制备方法 | |
CN103271274B (zh) | 一种营养保健粥 | |
EP3777869B1 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
WO2020118576A1 (zh) | 胚芽乳酸杆菌twk10在制备抗运动后发炎或降体脂组合物的用途 | |
WO2024149132A1 (zh) | 一种益生菌蛋白复合维生素及其制备方法 | |
KR101884634B1 (ko) | 체중 조절 효과를 지닌 유산균 발효액 | |
KR20100037310A (ko) | 김치 유산균을 이용한 액상 건강보조식품의 제조방법 | |
JP6675521B1 (ja) | 乳酸菌、血中鉄増加剤、及び貧血改善剤 | |
KR101421284B1 (ko) | 변비 개선용 조성물 및 이의 제조방법 | |
KR101779719B1 (ko) | 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물 | |
WO2022196488A1 (ja) | Qolを改善するための組成物 | |
JP7475155B2 (ja) | 持久力向上用組成物 | |
CN117460428A (zh) | Gos预调理的罗伊氏乳杆菌和最终制剂中的gos | |
KR20100037309A (ko) | 유산균을 이용한 환형 건강보조식품의 제조방법 | |
KR102531783B1 (ko) | 노을찰 수수를 포함하는 장 기능 개선용 조성물 | |
TWI815258B (zh) | 益生元組合物及木豆屬組合物用於調整腸胃道菌相之用途 | |
KR102678008B1 (ko) | 버섯균사체 함유 소화촉진용 건강보조식품 조성물 | |
CA3065189A1 (en) | Composition for recovering from fatigue and/or preventing fatigue accumulation | |
WO2024055983A1 (zh) | 南瓜籽蛋白组合物和其应用 | |
KR102439609B1 (ko) | 새싹 보리순 함유 분말 요거트 및 제조 방법 | |
WO2023068374A1 (en) | Composition for promoting the assimilation of an oligosaccharide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019559123 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19849264 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217005716 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019849264 Country of ref document: EP Effective date: 20210317 |